Share This Page

 
Now on Twitter!

Follow us: ChinaBio

In the News

Mr. Bio in China
Greg Scott interviewed by Mendelspod

Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>> Download now...
Print

Featured Event...


ChinaBio® Partnering Forum 2012

May 23-24, 2012 | Suzhou, China
ChinaBio® LLC and EBD Group will host their fourth ChinaBio® Partnering Forum in China to meet the needs of biotech and pharma companies as well as developers of early stage technology looking for funding and strategic partnerships. ChinaBio® Partnering Forum is the largest partnering conference in China, drawing more than 700 delegates and 400 companies from all over the world in 2012. Companies and researchers with novel technologies interested in partnering their technologies or products, initiating strategic alliances, or tapping into the global financing network are welcome to apply to present. With over one-third of the attendees being C-level decision makers, ChinaBio® Partnering Forum is the event to get partnerships started in China.

To find out more about presenting to international pharma, click here!

>> See  http://www.cbpf2012.com/ for more information.

Recent Articles

  The Week in Review: Seven China Researchers Land $650,000 Howard Hughes Research Grants (in: Week in Review)
Jan 28, 2012
Seven early-career China researchers landed $650,000 grants from the Howard Hughes Medical Institute, four of them are part of Beijing’s National Institute of Biological Sciences; EntreMed landed $10 million from a group of investors with China roots; Saladax Biomedical believes China will be a big market for the company’s diagnostic assays; SuperNova Diagnostics® is developing a point of care platform based on LCD technology; and Syneron Medical received SFDA approval for five aesthetic dermatology devices. More details….

Stock Symbols: (NSDQ: ENMD) (NSDQ: ELOS)

Share this with colleagues:  

  For Saladax Biomedical, China Could Be the Largest Market (in: Featured Companies)
Jan 27, 2012
Saladax Biomedical, a Bethlehem, Pennsylvania medical diagnostic reagent developer and manufacturer, believes China will be a big part of the company’s future. Edward L. Erickson, CEO of Saladax, told ChinaBio® Today in an exclusive interview, “The volume of the market in China for our products appears to be larger than the US and Europe put together.” Saladax makes MyCare™ therapeutic dose management products, and its major product is currently My5-FU™, a dose management test for 5-FU chemotherapy. More details....

Share this with colleagues:  

  Seven Young China Scientists Given $650,000 Howard Hughes Awards (in: News & Analysis)
Jan 26, 2012
The Howard Hughes Medical Institute handed out 28 grants to young scientists who came to the US for their education and then returned to their native countries to continue their work. Of the total, seven – one in four – came from China. And four of the seven have found a home at Beijing’s National Institute of Biological Sciences. The awards carry a financial prize of $650,000 over five years. More details....

Share this with colleagues:  

  Syneron Announces SFDA Approval for Five Aesthetic Machines (in: Trials & Approvals)
Jan 25, 2012
Syneron Medical, an Israeli company that makes aesthetic devices, received SFDA approval for five of the company’s products: eLaser, eLight, eMatrix, eMax and VelaShape systems. The company said the approvals constituted a “significant” expansion of its China product offerings. Syneron began marketing its products in China in 2008. More details....

Stock Symbol: (NSDQ: ELOS)

Share this with colleagues:  

  SuperNova Developing Point of Care Diagnostics Technology (in: Featured Companies)
Jan 24, 2012
SuperNova Diagnostics®, a US-based, global diagnostics company with deep China connections, is developing a point of care platform based on LCD technology. The device combines ease of use with low cost – a seemingly unbeatable combination. And it is now moving toward production. “It’s going to be a good year for Supernova Diagnostics,” said Neil Campbell, CEO and Co-Founder of the company in an exclusive ChinaBio® Today interview. “There aren’t a lot of technologies out there that can do what we do.” More details....

Share this with colleagues:  

  EntreMed Raises $10 Million from China-Connected Investors (in: Deals & Financings)
Jan 23, 2012
EntreMed, a clinical stage US biotech, landed $10 million from a group of investors with China roots. The investors included Tak W. Mak, PhD, a renowned cancer scientist who discovered EntreMed’s leading drug candidate, ENMD-2076. Dr. Mak is a previous investor in EntreMed and is also a part of a company that owns the China rights to ENMD-2076. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  

  The Week in Review: Xizang Haisco Pharma Completes $127 Million IPO (in: Week in Review)
Jan 21, 2012
Xizang Haisco Pharma, a Tibetan TCM company, staged a $127 million IPO in Shenzhen; Sanjiu Medical and Pharma expects to spend between $94.7 and $110.5 million to buy Shandong Shunfeng Pharma; Da An Gene formed a diagnostics JV with Life Technologies of San Diego; Jiangsu Kanion Pharma transferred the global ex-China rights for three oncology drug candidates to NewGen Therapeutics of California; ShangPharma reached the first milestone in its mAb partnership with Jiangsu Hengrui Medicine; Quintiles opened a back office center in Dalian, a northeast China city; Novartis received SFDA approval for Lucentis, a treatment for wet AMD, and will launch its diabetes drug, Galvus, in China; Xiamen Innovax Biotech was granted SFDA approval for a hepatitis E vaccine; and Drs. Zhen-Yi Wang and Zhu Chen were awarded a prestigious US prize for their groundbreaking work with a leukemia sub-type. More details….

Stock Symbols: (SHE: 002653) (SHE: 000999) (SHE: 002030) (NSDQ: LIFE) (SHA: 600557) (NYSE: SHP) (NYSE: NVS)

Share this with colleagues:  

  China Scientists Given US Award for Cancer Breakthrough (in: Featured Companies)
Jan 20, 2012
Two China scientists have been awarded a prestigious US prize for their groundbreaking work with a form of leukemia. By combining traditional Chinese medicine and western approaches, they increased the five-year survival rate of acute promyelocytic leukemia (APL) from 25% to an astonishing 95%. In recognition of their contribution, Drs. Zhen-Yi Wang and Zhu Chen were named recipients of the 7th Szent-Györgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research in the US. More details....

Share this with colleagues:  

  Sanjiu Pharma to Bid up to $110 Million for Shunfeng Pharma (in: Deals & Financings)
Jan 20, 2012
Sanjiu Medical and Pharmaceutical expects to spend between 600 and 700 million RMB ($94.7 - $110.5 million) in its bid for a 99.83% stake in Shandong Shunfeng Pharmaceutical, the beleaguered medicated skin care company. Shufeng Pharma has put itself up for auction because disgruntled shareholders are upset with the company’s management. It established a 600 million RMB base price. Sanjiu asked shareholders for permission to spend up to 700 million RMB on the acquisition. More details....

Stock Symbol: (SHE: 000999)

Share this with colleagues:  

  Jiangsu Kanion Out-licenses 3 Molecules to NewGen Therapeutics (in: Deals & Financings)
Jan 19, 2012
Jiangsu Kanion Pharma has transferred the global ex-China rights for three small molecule oncology drug candidates to a newly formed California startup, NewGen Therapeutics, in exchange for a minority position in NewGen. The CEO of Kanion USA, Wang Shen, is a co-founder and VP of R&D at NewGen. In China, Kanion is known mainly as a TCM company. More details....

Stock Symbol: (SHA: 600557)

Share this with colleagues:  

 
more articles >>
Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners